STOCK TITAN

Alto Neuroscience (NASDAQ: ANRO) CEO has shares withheld for taxes

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Alto Neuroscience, Inc. reported that President and CEO Amit Etkin had 6,227 shares of common stock withheld on March 1, 2026 to cover taxes upon vesting of previously reported restricted stock units. The shares were valued at $19.69 per share and the filing notes this was not an open market transaction. After this tax-withholding disposition, Etkin directly owned 1,233,949 common shares.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Etkin Amit

(Last) (First) (Middle)
C/O ALTO NEUROSCIENCE, INC.
650 CASTRO STREET, SUITE 450

(Street)
MOUTAIN VIEW CA 94041

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Alto Neuroscience, Inc. [ ANRO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT AND CEO
3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/01/2026 F 6,227(1) D $19.69 1,233,949 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of common stock withheld for payment of taxes upon vesting of restricted stock units previously reported in Table I and does not represent an open market transaction by the reporting person.
Remarks:
/s/ Erin R. McQuade, Attorney-in-Fact 03/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Alto Neuroscience (ANRO) disclose for Amit Etkin?

Alto Neuroscience disclosed that CEO Amit Etkin had 6,227 common shares withheld to cover taxes on vesting restricted stock units. The shares were valued at $19.69 each and the event was administrative, not an open market trade.

Was the Alto Neuroscience (ANRO) CEO’s Form 4 transaction an open market sale?

No, the Form 4 states the 6,227 shares were withheld to pay taxes on vesting RSUs and explicitly says it was not an open market transaction. It reflects tax withholding mechanics rather than a discretionary stock sale.

How many Alto Neuroscience (ANRO) shares does CEO Amit Etkin own after this filing?

After the tax-withholding disposition, CEO Amit Etkin directly owned 1,233,949 shares of Alto Neuroscience common stock. This figure reflects his post-transaction direct holdings as reported in the Form 4 insider filing.

What price per share was used in the Alto Neuroscience (ANRO) CEO tax withholding?

The Form 4 reports a price of $19.69 per share for the 6,227 Alto Neuroscience common shares withheld to satisfy tax obligations on vested restricted stock units. This value is used solely for the tax-withholding calculation.

What does transaction code F mean in the Alto Neuroscience (ANRO) Form 4?

Transaction code F on the Form 4 indicates shares were disposed to pay an exercise price or tax liability. For Alto Neuroscience, it reflects shares withheld from CEO Amit Etkin to cover taxes on vested restricted stock units.
Alto Neuroscienc

NYSE:ANRO

ANRO Rankings

ANRO Latest News

ANRO Latest SEC Filings

ANRO Stock Data

639.35M
27.16M
Biotechnology
Pharmaceutical Preparations
Link
United States
MOUNTAIN VIEW